Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab (Humira) add-on therapy in severe persistent therapy-resistant asthma
2005-005544-79Phase 2Terminated
- Sponsor
- RCSI Clinical Research Centre
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of adalimumab in severe asthma and asthma, sponsored by RCSI Clinical Research Centre. Primary endpoints: Reduction in tissue eosinophils and CD4+ lymphocytes and Safety of adalimumab in severe asthma. Started Jan 2006; status: terminated.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2005-005544-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005544-79.